Gilead Sciences, Inc (NASDAQ: GILD)’s stock price has plunge by 2.11relation to previous closing price of 93.07. Nevertheless, the company has seen a 3.47% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-01-25 that For income investors, closed-end funds, or CEFs, remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. CEFs are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer “excess” discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds.
Is It Worth Investing in Gilead Sciences, Inc (NASDAQ: GILD) Right Now?
The price-to-earnings ratio for Gilead Sciences, Inc (NASDAQ: GILD) is above average at 1071.36x, Company’s 36-month beta value is 0.19.Analysts have differing opinions on the stock, with 13 analysts rating it as a “buy,” 4 as “overweight,” 12 as “hold,” and 0 as “sell.”
The public float for GILD is 1.24B, and currently, short sellers hold a 2.06% ratio of that floaft. The average trading volume of GILD on January 27, 2025 was 6.95M shares.
GILD’s Market Performance
GILD stock saw an increase of 3.47% in the past week, with a monthly gain of 1.75% and a quarterly increase of 8.94%. The volatility ratio for the week is 1.57%, and the volatility levels for the last 30 days are 1.73% for Gilead Sciences, Inc (GILD). The simple moving average for the past 20 days is 3.24% for GILD’s stock, with a 20.11% simple moving average for the past 200 days.
Analysts’ Opinion of GILD
Many brokerage firms have already submitted their reports for GILD stocks, with Morgan Stanley repeating the rating for GILD by listing it as a “Overweight.” The predicted price for GILD in the upcoming period, according to Morgan Stanley is $113 based on the research report published on January 10, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see GILD reach a price target of $109. The rating they have provided for GILD stocks is “Buy” according to the report published on December 10th, 2024.
Wolfe Research gave a rating of “Outperform” to GILD, setting the target price at $110 in the report published on November 15th of the previous year.
GILD Trading at 3.52% from the 50-Day Moving Average
After a stumble in the market that brought GILD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.91% of loss for the given period.
Volatility was left at 1.73%, however, over the last 30 days, the volatility rate increased by 1.57%, as shares surge +1.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.04% lower at present.
During the last 5 trading sessions, GILD rose by +3.50%, which changed the moving average for the period of 200-days by +35.90% in comparison to the 20-day moving average, which settled at $92.05. In addition, Gilead Sciences, Inc saw 2.88% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GILD starting from Dickinson Andrew D, who sale 2,500 shares at the price of $91.35 back on Jan 15 ’25. After this action, Dickinson Andrew D now owns 129,873 shares of Gilead Sciences, Inc, valued at $228,375 using the latest closing price.
ANDREW DICKINSON, the Officer of Gilead Sciences, Inc, proposed sale 2,500 shares at $91.35 during a trade that took place back on Jan 15 ’25, which means that ANDREW DICKINSON is holding shares at $228,375 based on the most recent closing price.
Stock Fundamentals for GILD
Current profitability levels for the company are sitting at:
- 0.3 for the present operating margin
- 0.78 for the gross margin
The net margin for Gilead Sciences, Inc stands at 0.0. The total capital return value is set at 0.2. Equity return is now at value 0.62, with 0.22 for asset returns.
Based on Gilead Sciences, Inc (GILD), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at 0.43. The debt to equity ratio resting at 1.26. The interest coverage ratio of the stock is 8.56.
Currently, EBITDA for the company is 10.5 billion with net debt to EBITDA at 4.65. When we switch over and look at the enterprise to sales, we see a ratio of 4.84. The receivables turnover for the company is 6.17for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.26.
Conclusion
In a nutshell, Gilead Sciences, Inc (GILD) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
